Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
$24.28
-5.5%
$20.72
$10.14
$28.42
$304.64M0.8678,223 shs163,459 shs
Cryoport, Inc. stock logo
CYRX
Cryoport
$6.04
-2.9%
$5.93
$4.58
$11.64
$302.83M1.92543,684 shs253,099 shs
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
$1.28
$1.38
$0.73
$3.17
$81.01M0.62317,814 shs178,565 shs
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
$5.04
-2.3%
$4.36
$2.86
$16.62
$344.84M2.03860,437 shs519,216 shs
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-5.53%-4.78%+10.87%+13.09%+96.76%
Cryoport, Inc. stock logo
CYRX
Cryoport
-2.89%-9.58%+8.05%-2.89%-47.57%
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
0.00%0.00%-5.33%-14.09%-58.84%
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
-2.33%+7.01%-0.10%+1.00%-45.28%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
4.4676 of 5 stars
4.64.00.04.62.70.80.0
Cryoport, Inc. stock logo
CYRX
Cryoport
3.0425 of 5 stars
4.41.00.00.03.22.50.6
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
1.1112 of 5 stars
3.00.00.00.02.81.70.0
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
2.4383 of 5 stars
3.53.00.00.02.72.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
3.22
Buy$41.8672.39% Upside
Cryoport, Inc. stock logo
CYRX
Cryoport
2.71
Moderate Buy$11.0082.12% Upside
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
2.00
Hold$11.00759.38% Upside
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
3.00
Buy$24.50386.11% Upside

Current Analyst Ratings Breakdown

Latest GALT, CDTX, CYRX, and OLMA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/23/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$31.00 ➝ $35.00
5/23/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$35.00
5/16/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$35.00 ➝ $50.00
5/14/2025
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$20.00 ➝ $18.00
5/14/2025
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$25.00 ➝ $22.00
5/9/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$33.00 ➝ $35.00
5/9/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$46.00 ➝ $47.00
5/8/2025
Cryoport, Inc. stock logo
CYRX
Cryoport
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
5/5/2025
Cryoport, Inc. stock logo
CYRX
Cryoport
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $7.00
4/29/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$46.00 ➝ $46.00
4/28/2025
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
$302K1,008.75N/AN/A($1.82) per share-13.34
Cryoport, Inc. stock logo
CYRX
Cryoport
$232.13M1.30$0.36 per share16.95$9.45 per share0.64
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/AN/AN/AN/A($1.01) per shareN/A
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
N/AN/AN/AN/A$4.61 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-$22.93M-$29.47N/AN/AN/A-289.05%-69.64%-33.73%8/11/2025 (Estimated)
Cryoport, Inc. stock logo
CYRX
Cryoport
-$99.59M-$2.34N/AN/AN/A-70.08%-13.35%-6.43%8/5/2025 (Estimated)
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-$41.07M-$0.72N/AN/AN/AN/AN/A-163.15%8/11/2025 (Estimated)
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
-$96.65M-$2.01N/AN/AN/AN/A-53.56%-47.86%8/5/2025 (Estimated)

Latest GALT, CDTX, CYRX, and OLMA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-$0.20-$0.15+$0.05-$0.15N/AN/A
5/13/2025Q1 2025
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
-$0.49-$0.36+$0.13-$0.36N/AN/A
5/8/2025Q1 2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-$5.45-$1.66+$3.79-$1.66N/AN/A
5/7/2025Q1 2025
Cryoport, Inc. stock logo
CYRX
Cryoport
-$0.23-$0.22+$0.01-$0.28$56.19 million$41.04 million
3/31/2025Q4 2024
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-$0.16-$0.19-$0.03-$0.19N/AN/A
3/18/2025Q4 2024
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
-$0.63-$0.51+$0.12-$0.51N/AN/A
3/6/2025Q4 2024
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-$5.28-$5.38-$0.10-$5.37N/AN/A
3/4/2025Q4 2024
Cryoport, Inc. stock logo
CYRX
Cryoport
-$0.33-$0.42-$0.09-$0.42$58.71 million$59.53 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
N/AN/AN/AN/AN/A
Cryoport, Inc. stock logo
CYRX
Cryoport
N/AN/AN/AN/AN/A
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/AN/AN/AN/AN/A
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
N/A
3.54
3.54
Cryoport, Inc. stock logo
CYRX
Cryoport
0.48
5.70
5.32
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/A
1.13
1.13
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
N/A
7.10
7.10

Institutional Ownership

CompanyInstitutional Ownership
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
35.82%
Cryoport, Inc. stock logo
CYRX
Cryoport
92.90%
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
11.68%
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
91.78%

Insider Ownership

CompanyInsider Ownership
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
3.89%
Cryoport, Inc. stock logo
CYRX
Cryoport
10.00%
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
50.10%
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
19.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
9012.55 million6.51 millionNo Data
Cryoport, Inc. stock logo
CYRX
Cryoport
1,02050.14 million44.44 millionOptionable
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
963.29 million31.32 millionOptionable
Olema Pharmaceuticals, Inc. stock logo
OLMA
Olema Pharmaceuticals
7068.42 million46.18 millionOptionable

Recent News About These Companies

Q2 EPS Estimate for Olema Pharmaceuticals Raised by Analyst

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cidara Therapeutics stock logo

Cidara Therapeutics NASDAQ:CDTX

$24.28 -1.42 (-5.53%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$24.35 +0.07 (+0.29%)
As of 05/23/2025 05:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Cryoport stock logo

Cryoport NASDAQ:CYRX

$6.04 -0.18 (-2.89%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$6.04 0.00 (0.00%)
As of 05/23/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Galectin Therapeutics stock logo

Galectin Therapeutics NASDAQ:GALT

$1.28 0.00 (0.00%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$1.27 -0.01 (-0.39%)
As of 05/23/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Olema Pharmaceuticals stock logo

Olema Pharmaceuticals NASDAQ:OLMA

$5.04 -0.12 (-2.33%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$5.04 0.00 (-0.10%)
As of 05/23/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.